(Q45105237)

9 December 2017

title

Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis (English)

1 reference

9 December 2017

0 references

Cauza E

1

1 reference

9 December 2017

Etemad M

2

1 reference

9 December 2017

Winkler F

3

1 reference

9 December 2017

Hanusch-Enserer U

4

1 reference

9 December 2017

Partsch G

5

1 reference

9 December 2017

Noske H

6

1 reference

9 December 2017

Dunky A

7

1 reference

9 December 2017

publication date

1 October 2004

1 reference

Journal of Clinical Pharmacy and Therapeutics

9 December 2017

published in

1 reference

9 December 2017

volume

29

1 reference

9 December 2017

issue

5

1 reference

9 December 2017

page(s)

431-436

1 reference

Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption

9 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2004.00584.X

The management of Paget's disease of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2004.00584.X

Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2004.00584.X

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2004.00584.X

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2004.00584.X

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2004.00584.X

Cyclical pamidronate infusions in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2004.00584.X

Efficacy and tolerability of cyclical intravenous pamidronate in patients with low bone mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2004.00584.X

Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2004.00584.X

Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2004.00584.X

Nonclinical model for assessing gastric effects of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2004.00584.X

Antifracture efficacy of antiresorptive agents are related to changes in bone density.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2004.00584.X

10.1111/J.1365-2710.2004.00584.X

21 January 2018

Identifiers

DOI

1 reference

9 December 2017

1 reference